Monoclonal antibody successes in the clinic

Article Abstract:

Therapeutic monoclonal antibodies (mAbs) have developed into a beneficial and profitable group of products, although it had an inauspicious beginning in the 1980s. Monoclonal antibodies comprise the majority of recombinant proteins currently in the clinic, with more than 150 products in studies sponsored by companies located worldwide.

Management dynamics, Management, Company business management

---

The patentability of antibodies in the United States

Article Abstract:

Two court cases, Noelle v. Lederman and SmithKline Beecham v. Apotex, in the US attracts attention on the patentability of antibodies. The subtleties surrounding application of the US patent statues 35 USC [section] 102, 103, 112 greatly affect the patentability of antibodies.

United States, Patents & copyrights, Intellectual property

---

Similar abstracts:

• Abstracts: Empowering the inventor: The case of monoclonal antibodies. Flexibility: The guiding principle for antibody manufacturing

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.